High-Power, Short-Duration Ablation in Treatment of Patients With Atrial Fibrillation
NCT06415149 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 185
Last updated 2024-05-30
Summary
Atrial fibrillation (AF) stands as the most common type of cardiac arrhythmia. The frequency of AF in the overall population is 1-2%, with the incidence rate increasing with age from 0.5% in the 40-50 years old to 5-15% in those aged 80. \[According to current recommendations for catheter ablation (CA) in patients with AF, the isolation of the pulmonary veins (PV) is a pivotal aspect of treating this arrhythmia. Despite recent advancements, 20-45% of patients experience recurrences after PV isolation. According to the study by Wasmer K. et al., it was demonstrated that most patients with recurrent AF after PVI showed at least one reconnected vein during redo procedures. The primary cause of recurrences is the restoration of conduction, attributed to endurable isolation (non-transmural, intermittent RF). Numerous approaches have been presented to enhance the outcomes of surgical treatment for AF, such as the CLOSE protocol and Ablation Index (AI) . CLOSE protocol represents an approach aimed at isolating the PV ostia through precise continuous (distance between points ≤ 6 mm) radiofrequency intervention, achieving target ablation index values of ≥ 400au for the posterior wall and ≥ 500au for the anterior wall. The Ablation Index is a marker of quality lesion formation, providing a visual representation of the lesion based on the integration of power, contact force, and time parameters, which is displayed on the CARTO® 3 system (Biosense Webster).
Throughout radiofrequency ablation, electromagnetic energy undergoes conversion into thermal energy, leading to tissue damage and temperature elevation. The temperature elevation process encompasses two stages: resistive heating, impacting surface tissues (1-2mm), and conductive heating, which facilitates the transfer of heat from surface tissues to underlying tissues.
In the presence of good catheter-endocardium contact (25%), only 9% of the power is effectively delivered to the endocardium. For instance, at a power level of 30 watts and optimal contact (25%) with the endocardium, merely 2.7 watts are transferred to the endocardial tissue. When applying 30 watts of power for 30 seconds, a total energy delivery of 900 joules occurs, with only 90 joules being imparted to the endocardium. Similarly, at 50 watts for 10 seconds, only 45 joules of energy are transmitted to the endocardium. When operating at 10 watts, the catheter temperature elevates by 13°C. Consequently, at 30 watts, the temperature reaches 39°C, and at 50 watts, it rises to 65°C. The formation of an irreversible lesion necessitates a temperature exceeding 50°C. During standard radiofrequency ablation (RFA) procedures with power settings ranging from 20 to 45 watts and a duration of 20 to 60 seconds, the formation of ablation points predominantly occurs during the conductive heating phase.
High power short duration ablation (HPSD) is an approach that reduces the conductive heating phase while increasing the resistive heating phase. This results in an expanded area of lesion, facilitating the formation of transmural lesions in the atrial myocardium with irreversible tissue damage and reduced risk to surrounding structures, such as thermal injury to the esophagus.
The strategy of HPSD ablation was developed to overcome limitations of the traditional approach. However, much remains unknown regarding the safety and effectiveness of this approach. Additionally, the question for the optimal interventional treatment method for atrial fibrillation (AF) and the selection of the optimal RF energy for pulmonary vein isolation still require confirmation. This forms the basis for our research objective.
Conditions
- Atrial Fibrillation
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
Interventions
- PROCEDURE
-
High power short duration ablation with 50 W
Group 1 (n=95): pulmonary vein isolation for treatment of atrial fibrillation was performed with power of 50 watts in Ia subgroup (n=55) AI (ablation index) was 400-450 arbitrary units (au) for the posterior wall and 500-550 au for the anterior wall, in Ib (n=40) AI was 400-450 au for the posterior wall and 450-500 au for the anterior wall.
- PROCEDURE
-
High power short duration ablation with 45 W
Group 2 (n=90): Pulmonary vein islolation was performed at a power of 45 watts, in IIa subgroup (n=50) with target AI of 400-450 au for the posterior wall and 500-550 au for the anterior wall in IIb (n=40) AI of 400-450 au for the posterior wall and 450-500 au for the anterior wall.
Sponsors & Collaborators
-
City Clinical Hospital No.1 named after N.I. Pirogov
collaborator OTHER -
People's Friendship University of Russia
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-01
- Primary Completion
- 2023-02-01
- Completion
- 2024-03-01
Countries
- Russia
Study Locations
More Related Trials
-
Application Value of Whole-procedure Optimization for Catheter Ablation of Atrial Fibrillation
NCT06145906 ·Status: RECRUITING
-
Cryoablation in Patients With Atrial Flutter
NCT01563848 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium
NCT06253000 ·Status: RECRUITING ·Phase: NA
-
Cryoballoon Ablation of Pulmonary Veins After Failed RF Ablation in Patients With Paroxysmal AF
NCT01611701 ·Status: COMPLETED ·Phase: PHASE3
-
High-Power Short-Duration Radiofrequency Ablation in Patients With Typical Atrial Flutter
NCT05777850 ·Status: UNKNOWN ·Phase: NA
-
Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation
NCT01521988 ·Status: COMPLETED ·Phase: NA
-
Substrate Guided Ablation Therapy for Atrial Fibrillation
NCT04657978 ·Status: UNKNOWN
-
Non-fluoroscopy Ablation of AF/AT
NCT03750435 ·Status: UNKNOWN ·Phase: NA
-
Cryoballoon Ablation as First Line Treatment of Atrial Flutter
NCT03401099 ·Status: COMPLETED ·Phase: NA
-
Effect of Mechanical Ventilation on Radiofrequency Ablation in Atrial Fibrillation
NCT06791915 ·Status: RECRUITING
-
Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation With Heart Failure
NCT04461691 ·Status: COMPLETED ·Phase: NA
-
Cryoablation as Standard Treatment of Atrial Flutter
NCT01604369 ·Status: COMPLETED ·Phase: NA
-
Study Comparing Pulmonary Vein Isolation With the Cryoballoon, Radiofrequency Energy, or Both in the Treatment of Atrial Fibrillation (AF)
NCT01038115 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Different Ablation Strategies for Controlling Atrial Fibrillation
NCT00379301 ·Status: COMPLETED ·Phase: NA
-
Atrial Fibrillation Ablation: Radiofrequency or Cryoablation?
NCT03774550 ·Status: COMPLETED
-
Durability of Pulmonary Vein Isolation Following Cryoablation for Treatment of Paroxysmal Atrial Fibrillation
NCT01645917 ·Status: COMPLETED ·Phase: PHASE4
-
Cryoballoon vs. Rhythmia Guided Ablation for Recurrent AFib
NCT03811795 ·Status: UNKNOWN ·Phase: NA
-
Cryoballoon Atrial Fibrillation Ablation Registry
NCT03040037 ·Status: COMPLETED
-
Randomized Study of Radiofrequency- vs. Cryo-Ablation for Typical Isthmus-Dependent Atrial Flutter
NCT00196170 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Catheter Ablation on Left Atrial Function in Persistent Atrial Fibrillation
NCT03443232 ·Status: COMPLETED ·Phase: NA
-
Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration
NCT01913522 ·Status: COMPLETED ·Phase: NA
-
Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of AF
NCT01183091 ·Status: COMPLETED
-
High Power Short Duration Ablation Compared to Moderate Power Long Duration Ablation for Pulmonary Vein Isolation
NCT05959798 ·Status: COMPLETED
-
Safety and Efficacy of Catheter Ablation of Idiopathic Ventricular Arrhythmias Arising From Cardiac Outflow Tracts
NCT03258112 ·Status: WITHDRAWN ·Phase: NA
-
Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation
NCT01229475 ·Status: UNKNOWN ·Phase: NA